Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Date:9/19/2011

mia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); uncertainties related to the regulatory process in the United States, Europe and Japan; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website and the FDA website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
5. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
6. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
7. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
9. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
10. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
11. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... WASHINGTON , June 30, 2015  NASA astronaut ... launch next month on his first mission to the ... interviews from 8 to 9 a.m. EDT Tuesday, July 7. ... Center in Star City, Russia . The ... on NASA Television highlighting his mission training. To ...
(Date:6/30/2015)... YORK , June 30, 2015  Today, Americord Registry, ... U.S., announced Andrew Horne , a partner at Kirkland ... Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... to Americord,s Advisory Board," says Martin Smithmyer , CEO ... in his legal career that will assist Americord,s growth and ...
(Date:6/30/2015)... ... 2015 , ... With its latest polyacrylonitrile (PAN) membrane, Sterlitech ... flow rates in comparison to nylon or polyethersulfone (PES). Its unique nanofiber ... liquid flow while trapping particulates as small as 0.2 micron in width. , ...
(Date:6/30/2015)... ... ... The maximum number of shares proposed to be purchased in the tender offer ... stock). On June 29, 2015, the last trading day prior to the commencement of ... was $2.29 per share. , The tender offer will expire on July 28, 2015 ...
Breaking Biology Technology:NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... WA, Jan. 28 /PRNewswire-FirstCall/ - Oncothyreon Inc. (the,"Company") ... specializing,in the development of innovative therapeutic products for ... the Company,s clinical development plans,and corporate objectives for ... targeted small molecules with the potential to,improve the ...
... - European Patent Office Grants Patent for Treatment of ... the field of human gene therapy, today,announced that the ... patent for the treatment of Non-Alcoholic Steatotic Hepatitis,(NASH) with ... pending with,the U.S. Patent and Trademark Office., The ...
... 0641-2450-45 and 0641-2450-41;, LOTS: 107054, 117085, 047056, 097081, 107024, 107064, ... ... DEERFIELD, Ill., Jan. 25 Baxter Healthcare,Corporation has announced the voluntary recall ... vials. The company,began recalling the lots on January 17, 2008 as a ...
Cached Biology Technology:Oncothyreon highlights corporate and clinical objectives for 2008 2Oncothyreon highlights corporate and clinical objectives for 2008 3Oncothyreon highlights corporate and clinical objectives for 2008 4Oncothyreon highlights corporate and clinical objectives for 2008 5AMT's Lead Product Poised to Address Major Liver Disease 2AMT's Lead Product Poised to Address Major Liver Disease 3Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials 2
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 2015 Research and ... the "Huawei Ascend Mate 7 Fingerprint Sensor ... offering. Huawei,s technological choice for the ... than Apple,s and Samsung,s one. The Ascend Mate ... Fingerprint Cards, a main actor in capacitive sensing ...
(Date:6/23/2015)... 23, 2015   Valencell, a leader ... of a recent study that illustrates its PerformTek ... during activity. In a study conducted at Valencell,s ... with the Apple Watch against a chest strap ... during activity. The study demonstrated that Valencell,s biometric ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... research about pollution in the Ganges River has reached ... MSU scientists who study the 1,500-mile river. "It,s ... by a government institute in India and being presented ... in microbiology. "Lots of things get done judicially in ...
... feed on seaweed could help in the disposal of ... study by researchers in China and Japan. The discovery ... Inderscience publication. Shinichi Nagata of the Environmental Biochemistry ... Shimane University and at Nankai University, China, explain that ...
... Men whose prostate cancer screenings show high grade prostatic ... between diagnoses they are told prostate cancer has ... advised to undergo repeated needle biopsies as a precaution. ... of distinguishing between HG-PIN lesions destined to become cancerous ...
Cached Biology News:Montana State University research reaches Supreme Court of India 2Wakame waste 2Biomarker predicts malignancy potential of HG-PIN lesions in the prostate 2Biomarker predicts malignancy potential of HG-PIN lesions in the prostate 3
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Gamma delta T Lymphocytes Purified Anti-Porcine clone MAC320, Isotype Rat IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: